Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab
ReutersFeb 2, 2026 12:26 PM
Feb 2 (Reuters) - Skye Bioscience Inc SKYE.O:
SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RESULTS FOR NIMACIMAB IN COMBINATION WITH SEMAGLUTIDE
SKYE BIOSCIENCE INC - 22.3% WEIGHT LOSS AT 52 WEEKS WITH NIMACIMAB + SEMAGLUTIDE (2.4 MG) COMBINATION
SKYE BIOSCIENCE INC - FULL TOPLINE REPORTING OF CBEYOND PHASE 2A DATA EXPECTED Q3 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Coca Cola (KO) Q4 Earnings Preview: Look for the Upside in the AI Initiatives, not in the Revenue and the EPS
Coca-Cola (KO) enters its fourth-quarter 2025 earnings call tomorrow with significant momentum. However, a fundamental shift is occurring.TradingKey
3 hours ago
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion TreTradingKey
17 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
